Pancreatic Cancer section

Prostate Cancer News & Features

Taxane Acute Pain Syndrome in Cancer Therapy: Occurrence, Impact on Quality of Life

Taxane Acute Pain Syndrome in Cancer Therapy: Occurrence, Impact on Quality of Life

Results of a prospective study of patients with breast or prostate cancer demonstrate the impact of taxane-based chemotherapy on quality of life.

Increased Monitoring Increases Cost, Not Quality of Care or Survival, in Prostate Cancer

Increased Monitoring Increases Cost, Not Quality of Care or Survival, in Prostate Cancer

In an evaluation of SEER-Medicare data, researchers sought to determine the benefits of extreme use of monitoring in patients with metastatic prostate cancer at the end of life on survival outcomes, quality of life, and costs.

Promising Phase 2 Results Lead to Fast Track Designation for Pancreatic Cancer Drug

Promising Phase 2 Results Lead to Fast Track Designation for Pancreatic Cancer Drug 

FDA Fast Track designation was supported by data from a Phase 2 study reviewing pamrevlumab in combination with gemcitabine and nab-paclitaxel.

Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance

Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance

ADT recipients reported worse subjective sleep disturbance, researchers found.

Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC

Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC

According to the FDA, the drug approval is the first to use the end point of metastasis-free survival.

Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer

Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer

Aggressive therapy does not appear to be more beneficial than conservative androgen deprivation therapy alone, according to a study.

Single Screening for PSA Levels Does Not Improve Survival in Prostate Cancer

Single Screening for PSA Levels Does Not Improve Survival in Prostate Cancer

Researchers sought to determine the effect single PSA testing had on prostate cancer diagnosis, mortality, and all-cause mortality.

Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy

Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy

At $225 million per system, the precision of proton beam radiotherapy is not necessarily overshadowing its high costs. Yet ongoing studies seek to determine how this technology fits into current treatment regimens for prostate, breast, and other cancers.

Travel Distance to Prostate Cancer Treatment Influences Treatment Choice

Travel Distance to Prostate Cancer Treatment Influences Treatment Choice 

Long-distance travel was more strongly associated with definitive prostate SBRT use, researchers found.

Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer

Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer

SPARTAN phase 3 study shows that apalutamide prolongs metastasis-free survival and time to symptomatic progression compared with placebo among men with nonmetastatic CRPC.

Prostate Cancer Resources

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs